What do systematic reviews say?

Oral tetracycline vs topical clindamycin

• Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Low

Tetracycline + SRP vs SRP

The review found no eligible studies for this question.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  Included studies have not reported this outcome
  Studies not reported
  No studies found
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD -0.53 [-1.14, 0.08]
  1 study · 38 participants
  GRADE not reported

Tetracycline + SRP vs SRP

Tetracycline + SRP led to lower clinical attachment level (CAL) compared with SRP; GRADE not reported.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Intermediate-term (> 3 months to < 1 year)
  MD -1.90 [-2.17, -1.63]
  1 study · 26 participants
  GRADE not reported
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  MD -2.30 [-2.50, -2.10]
  1 study · 26 participants
  Very low
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD -0.92 [-2.38, 0.54]
  2 studies · 64 participants
  GRADE not reported

Tetracycline + SRP vs SRP

The review found no eligible studies for this question.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  Included studies have not reported this outcome
  Studies not reported
  No studies found

Tetracycline + SRP vs SRP

The review found no eligible studies for this question.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  Included studies have not reported this outcome
  Studies not reported
  No studies found

Tetracycline + SRP vs SRP

The review found no eligible studies for this question.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  Included study has not reported adverse events
  Studies not reported
  No studies found

Tetracycline + SRP vs SRP

The review found no eligible studies for this question.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  Included studies have not reported this outcome
  Studies not reported
  No studies found
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD -14.62 [-27.21, -2.03]
  1 study · 38 participants
  GRADE not reported

Tetracycline + SRP vs SRP

The review found no eligible studies for this question.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  Included studies have not reported this outcome
  Studies not reported
  No studies found

Macrolide+tetracycline vs macrolides

• Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 187 participants
  Very low

Macrolide+tetracycline vs macrolides

It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).

• Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
  OR 1 [0.52, 1.93]
  1 study · 198 participants
  Very low

Macrolide+tetracycline vs macrolides

• Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 182 participants
  Very low

Macrolide+tetracycline vs macrolides

It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).

• Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
  OR 1.63 [0.38, 7.02]
  1 study · 198 participants
  Very low

Macrolide+tetracycline vs macrolides

The review found no eligible studies for this question.

• Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nicotinamide plus tetracycline vs prednisone

It is very uncertain whether nicotinamide plus tetracycline changes disease control: complete response at 8 weeks: excluding dropouts compared with prednisone (very low certainty).

• Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
  RR 2.5 [0.37, 16.89]
  1 study · 18 participants
  Very low

Nicotinamide plus tetracycline vs prednisone

It is very uncertain whether nicotinamide plus tetracycline changes mortality at 6 months compared with prednisone (very low certainty).

• Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
  RR 0.18 [0.01, 3.85]
  1 study · 18 participants
  Very low

Nicotinamide plus tetracycline vs prednisone

The review found no eligible studies for this question.

• Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nicotinamide plus tetracycline vs prednisone

• Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Tetracycline suspension (250 mg, held in mouth 2 minutes then swallowed, four times daily for 5 days) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  5 days per outbreak
  A statistically significant difference was shown, in favour of tetracycline, for adjusted maximum ulcer size (P=0.034) and adjusted maximum pain (P=0.017).
  1 study
  GRADE not reported

Tetracycline suspension (250 mg, held in mouth 2 minutes then swallowed, four times daily for 5 days) vs placebo

Tetracycline suspension (250 mg, held in mouth 2 minutes then… showed no clear difference in average number of new lesions per week compared with placebo; GRADE not reported.

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  5 days per outbreak
  MD -0.47 [-1.34, 0.40]
  1 study
  GRADE not reported

Tetracycline suspension (250 mg, held in mouth 2 minutes then swallowed, four times daily for 5 days) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  5 days per outbreak
  Adverse event rates were comparable between groups.
  1 study
  GRADE not reported